Ulecaciclib is an orally active cyclin-dependent kinase (CDK) inhibitor with potential therapeutic applications in cancer treatment; it exhibits potent inhibitory activity against CDK2/CyclinA (Ki = 0.62 μM), CDK4/CyclinD1 (Ki = 0.2 nM), CDK6/CyclinD3 (Ki = 3 nM), and CDK7/CyclinH (Ki = 0.63 μM); it is capable of crossing the blood-brain barrier and demonstrates favorable pharmacokinetic properties.